Sodexo boasts a defensive profile and significant potential for operational improvement, with progress increasingly visible since Sophie Bellon’s arrival as CEO. These factors are set to endure, narrowing the gap with Compass, and its transformation into a catering pure player following Pluxee’s spin-off in early 2024 should facilitate the group’s rerating. Outperform rating reiterated and a target price € 98 following Pluxee’s spin-off (combined Sodexo + Pluxee target price of € 12...
Sodexo bénéficie d’un profil défensif et d’un fort potentiel d’amélioration opérationnelle, avec des progrès de plus en plus visibles depuis l’arrivée de Sophie Bellon comme CEO. Ceux-ci devraient se poursuivre, réduisant l’écart avec Compass, et sa transformation en un pure player, à la suite du spin-off de Pluxee début 2024, devrait faciliter son rerating boursier. Surperformance réitérée et OC à 98 € à la suite du spin-off de Pluxee (OC combinés Sodexo + Pluxee à 129 € vs OC de 118...
>Q1 solid performance, but impacted by China - The Q1 results of Siemens Healthineers were driven by a strong performance of Varian supported not only by a healthy underlying demand for radiation, but also by a comparatively low base in Q1 2023. Imaging had a solid performance impacted by China. Diagnostics showed some top-line stabilisation (2+2% y-o-y) excluding the antigen, which is also a move into the right direction in our view. No relief in China - ...
>Slight beat at group level - Q1 revenues of € 5,176m (+4.2% y-o-y) were 4%/1% ahead of ODDO BHF/consensus estimates. The comparable sales growth was 5.7% (vs 3.7%/5.2% expected) still impacted by headwind from the Covid antigen test. Excluding the test, comparable sales growth would have been at a solid 7.0%. The equipment book-to-bill was at a level of 1.14x, following 1.16x at the Q4 results. Adjusted EBIT of € 742m (+14.7% y-o-y, margin 14.3%) was 5%/0% vs expecta...
>Imaging – strong prospects driven by photon counting CT and MRI - The overall positive expectations for Imaging were confirmed. Innovations continue to be the driver of growth. Highlights were a deep discussion about Naeotom, the world’s first photon counting CT. The unique technology offers a significant higher resolution combined with a radiation dosage, which is c. 30% lower than the latest dual-source CT offering. We see a technological lead vs competitors for a ...
>Finish driven by Varian - Q4 2023/24 revenues of € 6,056m (+1.0% y-o-y) were driven by comparable sales growth of 7.5% still impacted by some headwind from the Covid antigen test. Excluding the test, comparable sales growth would have been at a strong 10.8%. The positive development was driven by Varian, which showed a very strong 29.8% comparable sales growth. Hence, we like the positive trend of the equipment book-to-bill, which climbed to a level of 1.16x vs 1.11x...
>Strong finish with beat on sales and adj. EBIT - Q4 revenues of € 6,056m (+1.0% y-o-y) were 2%/3% ahead of ODDO BHF/consensus estimates. The comparable sales growth was 7.5% (vs 4.3%/4.7% expected) impacted by headwind from the Covid antigen test. Excluding the test, comparable sales growth would have been at a strong 10.8%. The equipment book-to-bill was at a level of 1.16x, following 1.11x at the Q3 results. Adjusted EBIT of € 1,013m (+0.2% y-o-y, margin 16.7%) was...
Since its integration into our European Large Caps Convictions list on 11 January 2023, KPN has made a significant contribution to the list’s performance, thanks to its defensive profile and high dividend yield (11.33% total return). We have decided to take profits as the company is holding its Capital Market Day today. The outlook remains very bright, but the smaller-than-expected share buyback programme announced this morning in the group's press release could disappoint. - ...
Since its integration into our European Large Caps Convictions list on 11 January 2023, KPN has made a significant contribution to the list’s performance, thanks to its defensive profile and high dividend yield (11.33% total return). We have decided to take profits as the company is holding its Capital Market Day today. The outlook remains very bright, but the smaller-than-expected share buyback programme announced this morning in the group's press release could disappoint. - ...
>Q4 due 8 November – Solid quarter expected - Siemens Healthineers’ Q4 revenues of € 5,932m (-1.1% y-o-y, 1% vs consensus) should be driven by comparable sales growth of 4.3%, but should be hold back by forex headwind of 540bp. Imaging should show 7.9% comparable sales growth impacted by slight headwind from China. We forecast Diagnostics to be down by 13% on a comparable base, but to show some sequential improvement compared to Q3 (-20% y-o-y). On the other hand, Var...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.